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Abstract
Background: Mycobacterium chimaera is a recently described species within the Mycobacterium avium complex. Its
pathogenicity in respiratory tract infection remains disputed. It has never been isolated during cystic fibrosis
respiratory tract infection.
Case presentation: An 11-year-old boy of Asian ethnicity who was born on Réunion Island presented to our
hospital with cystic fibrosis after a decline in his respiratory function over the course of seven years. We found that
the decline in his respiratory function was correlated with the persistent presence of a Mycobacterium avium
complex organism further identified as M. chimaera.
Conclusion: Using sequencing-based methods of identification, we observed that M. chimaera organisms
contributed equally to respiratory tract infections in patients with cystic fibrosis when compared with M. avium
subsp. hominissuis isolates. We believe that M. chimaera should be regarded as an emerging opportunistic
respiratory pathogen in patients with cystic fibrosis, including young children, and that its detection warrants long-
lasting appropriate anti-mycobacterial treatment to eradicate it.
Introduction
Mycobacterium avium complex (MAC) organisms are
opportunistic pathogens, and their isolation from the
respiratory tract of cystic fibrosis (CF) patients correlates
with declining respiratory function [1]. Six of nine MAC
species have been described in the past five years [2-4],
but the spectrum of MAC organisms infecting CF
patients is not well established; only M. avium and
Mycobacterium intracellulare have been reported in
these patients [1,5].
Our reference mycobacteriology laboratory routinely
processes respiratory tract specimens collected from all
CF patients who are followed by the Cystic Fibrosis
Regional Reference Center in Marseilles, France. After
Ziehl-Neelsen staining, cultures were routinely per-
formed in BACTEC broth using the BACTEC 9000 MB
system (BD Biosciences, Sparks, MD, USA), subcultures
were grown on 5% sheep blood agar, and identification
w a sd o n eb yp a r t i a lrpoB-based sequencing [2]. Geno-
typing of the isolates was performed using multi-spacer
sequence typing (MST) [6]. The minimum inhibitory
concentrations were determined by 10-day incubation of
a 1 McFarland mycobacterial suspension at 37°C on 5%
sheep blood agar in the presence of the respective Etest
strip (AB Biodisk, Solna, Sweden). The susceptibility to
rifabutin was determined in BACTEC broth using the
BACTEC 9000 MB system by incubating a 1 McFarland
bacterial suspension with 1 μg/mL or 2 μg/mL rifabutin
for five days in the presence of a growth control.
Over a six-year period, five (4.3%) of 115 children with
CF had at least one respiratory tract specimen that was
positive for MAC. M. avium subsp. hominissuis was
found in two patients (with distinct MST48 and MST20
genotypes), Mycobacterium colombiense was found in
one patient, and Mycobacterium chimaera was found in
two additional patients (distinct MST33 and MST39
genotypes).
Case presentation
One of the latter five patients with CF described at the
end of the Introduction was an Asian boy born on
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deletion in the CFTR gene, which is diagnostic of CF.
He presented to our hospital when he was 11 years old
because he had started complaining of hemoptoic
cough. A physical examination revealed weight loss and
wheezing. After his arrival in metropolitan France, a
MAC organism further identified as genotype ST33 M.
chimaera was isolated from his respiratory tract (Figure
1). This isolate was susceptible to clarithromycin (3 μg/
mL), rifabutin (< 1 μg/mL), and ethambutol (2 μg/mL)
and was resistant to ofloxacin (> 32 μg/mL), streptomy-
cin (> 1024 μg/mL), doxycyclin (> 256 μg/mL), and
rifampicin (> 32 μg/mL). The patient was given rifabutin
and clarithromycin, but he interrupted this treatment
after two weeks. Six monthsl a t e rh i ss p u t u my i e l d e d
acid-fast bacilli that were identified as genotype MST33
M. chimaera after culture. The same antibiotic regimen
prescribed for six months yielded negative mycobacterial
cultures. Two years later a recurrent fever and cough
correlated with MST33 M. chimaera-positive cultures.
The patient once again interrupted his therapy of rifabu-
tin combined with clarithromycin, this time after four
months. Twenty-two months later the patient’sc o n d i -
tion severely worsened, as he had developed chronic
respiratory insufficiency exacerbated by bilateral pneu-
mothorax, which required non-invasive ventilatory sup-
port. From this period onward, insulin therapy became
necessary to achieve glycemic control, and his nutri-
tional condition justified the initiation of enteral feeding
by percutaneous gastrostomy. The thoracic computed
tomographic scan showed bronchiectasis, expanded
areas of condensation, and mediastinal polyadenopathy.
Acid-fast bacilli that were observed on sputum smears
were cultured and revealed to be MST33 M. chimaera
organisms. Rifabutin and clarithromycin were reintro-
duced, but sequential cultures remained positive. The
patient was registered in the national list of lung trans-
plant candidates.
During the whole treatment period, the microbiologi-
cal investigations of the respiratory tract specimens also
exhibited Pseudomonas aeruginosa, methicillin-
susceptible Staphylococcus aureus, Stenotrophomonas
maltophilia, and Aspergillus fumigatus.
Discussion
T h ep r e v a l e n c eo fM A Co r g a n i s m si np a t i e n t sw i t hC F
is highly variable, ranging from 9% in the US [1] to 1.5%
in France, and it was evaluated at 1.8% in southeast
France [5], where Marseilles is located, although our
data yielded a prevalence of 4.3% there. In France and
the US, M. avium has contributed to twice as many
positive samples as M. intracellulare [5,7]. However, the
identification of MAC organisms has relied on hybridi-
zation probe-based methods, which has misidentified M.
chimaera as M. intracellulare [3], thus preventing the
detection of M. chimaera in patients with CF. Using
sequence-based identification, we observed that M. chi-
maera organisms contribute equally to respiratory tract
infections in patients with CF compared with M. avium
subsp. hominissuis isolates.
The pathogenicity of M. chimaera remains controver-
sial. It has been reported to cause respiratory infections
in patients with pulmonary diseases other than CF,
including chronic obstructive pulmonary disease,
bronchiectasis, and cavitation [3]. Conversely, in two
studies with an aggregate of 97 non-CF patients OK,
only 3.3% infected with M. chimaera fulfilled the Ameri-
can Thoracic Society (ATS) criteria for MAC lung dis-
ease [8,9]. The patient described in our case report
eventually fulfilled the ATS criteria on the basis of posi-
tive cultures from at least two separate sputum samples.
Moreover, his M. chimaera infection relapsed every
time antibiotic treatment was interrupted, and this con-
tinuing infection correlated with a worsening condition
of the patient in the presenceo fa s s o c i a t e dp a t h o g e n s ,
which may have also contributed to this downward spir-
aling evolution [10].
Conclusion
We believe that M. chimaera should be regarded as an
emerging opportunistic respiratory pathogen in patients
with CF, including young children, and that its detection
Figure 1 Chronological representation of Mycobacterium chimaera respiratory tract infection in a CF patient. Arrows indicate requests for
mycobacterial detection in the sputum. Dotted arrows indicate negative culture. Filled arrows indicate positive culture for M. chimaera.+
indicates acid-fast bacilli stain seen upon direct microscopic examination of sputum samples. Antibiotic therapy is represented by black squares.
Duration of treatment (in weeks) is indicated above the brackets.
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Written informed consent was obtained from the
patient’s mother for publication of this case report and
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sent is available for review by the Editor-in-Chief of this
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